In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Clinical research heroes: Mitsu Rana
Mitsu Rana, Senior Director of Project Management, shares her perspective on the current state of clinical research and how it is adapting.
-
Glycomics applications reinforce precision medicine
Nicole A. Cowan explores how glycomics is joining genomics and proteomics in the study of disease mechanisms and the development of novel therapeutics.
-
.jpg?w=545&itok=wJUAgndi "IPT discussed in technical publications.")
The path to smarter digital health
Michael Phillips and Kevin Rooney discuss the use of artificial intelligence for the purposes of automation in digital health and pharma.
This article is taken from Innovations in Pharmaceutical Technology Autumn/Winter 2021, pages 39-41. Samedan Ltd
-
Clinical Researcher of the Year - The Americas 2021 winners announced
The evening was particularly successful for ICON plc, which won the coveted Clinical Research Company of the Year award for having the most successful finalists throughout the competition.
-
Video series: The 3 Cs" of the data journey"
This three part video series examines some of the factors that should be considered to ensure that clinical trial data captured via wearable devices, is monitored expeditiously and effectively.
-
Bringing the fight to antimicrobial resistance: What COVID-19 has taught us about how to face a growing emergency
Dr. Johan Du Toit, Executive Director, Internal Medicine, considers strategies from COVID era clinical trials for addressing the public health crisis of antimicrobial resistance.
-
-
Operationalising decentralised clinical trials
In this article, our experts discuss the challenges and change management approaches that ICON faced during the COVID-19 pandemic, and how we overcame them through the use of decentralised and hybrid clinical trials (see page 14).
-
4D pharma enlists ICON for upcoming phase I/II microbiome therapeutic combo study in urothelial carcinoma with Merck KGaA’s Bavencio
This article announces that 4D Pharma are working with ICON for an upcoming trial with its lead live biotherapeutic MRx0518 in combination with Merck KGaA’s Bavencio. (a subcription is required to view this article)
-
On the frontlines of the COVID-19 crisis
In this report, Dr Steve Cutler describes ICON’s efforts to combat the COVID-19 pandemic and how the crisis has pushed new digital technologies forward
.jpg?w=340&itok=h4kRVbXf "IPT discussed in technical publications."){kind=icon}
